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Plasma levels of bone Gla-protein reflect bone formation in patients on
chronic maintenance dialysis. Predictive value of plasma levels of bone
Gla-protein (BGP) for bone histology was evaluated in 30 chronically
dialyzed patients. All patients underwent bone biopsies and serum
biochemical parameters, including BUP, parathyroid hormone, and
alkaline phosphatase; calcium and phosphate were measured at the time
of biopsy. Bone histology showed renal osteodystrophy with low bone
turnover and osteomalacia (LT-ROD) in 13 patients, and renal
osteodystrophy with high bone turnover and prevailing hyperparathy-
roid bone disease (HT-ROD) in 17 patients. Values for BGP were above
normal in LT-ROD (47.3 7.9 vs. 6.8 0.2 ng/ml) and extremely
elevated in HT-ROD (831 170 ng/ml). Similar differences were not
found with the other serum biochemical parameters, even though BGP
correlated with parathyroid hormone (r = 0.64) and alkaline
phosphatase (r = 0.85). There were significant correlations between
BGP and cellular and non-cellular parameters of bone formation (r =
0.73 to 0.91). Weaker or no correlations were found between BGP and
histologic parameters of bone, reflecting mainly mineralization or
resorption. These correlations and the finding of significant differences
in plasma BGP between LT-ROD and HT-ROD indicate that plasma
levels of BGP reflect bone formation in uremia and predict underlying
bone histology.
Les taux plasmatiques de Ia Gal-proteine osseuse reflètent Ia formation
osseuse chez les malades en dialyse chronique. La valeur des taux
plasmatiques de Ia Gla-protcine osseuse pour Ia prediction de
l'histologie osseuse a été ëvaluée chez 30 hemodialyzes chroniques.
Une biopsie osseuse a été pratiquée chez tous les malades et les
prélèvements sanguins pour Ia mesure de Ia BGP, parathormone,
alcaline phosphatase, calcium et phosphore ont été effectuCs au mo-
ment de Ia biopsie. L'histologie osseuse a révClé une ostéodystrophie
rénale a faible niveau de remodelage (LT-ROD) chez 13 malades et une
ostéodystrophie renal a haut niveau de remodelage avec hyper-
parathyroidisme (HT-ROD) chez 17 malades. Les taux de BGP étaient
au dessus de la normale chez les malades avec LT-ROD (47.3 7.9 vs.
6.8 0.2ng/ml) et extrCmement Clevés chez les malades avec HT-ROD
(831 170 ng/ml). Aucune difference entre les deux groupes n'a été
retrouvCe avec Ia parathormone ou alcaline phosphatase hien que BGP
soit correlée avec Ia parathormone (r = 0.64) et Ia phosphatase alcaline(r = 0.85). Des correlations significatives ont etC établies entre Ia BGP
et les paramCtres cellulaires et non cellulaires de Ia formation osseuse (r
0.73 a 0.91). Des correlations plus faibles ou une absence de
correlation ont etC trouvCes entre BGP et les paramètres histologiques
osseux de La minéralisation et de Ia resorption. Ces correlations et Ia
presence de differences significatives des taux plasmatiques de la BGP
entre LT-ROD et HT-ROD indiquent que Ia BGP plasmatique refiCtent
Ia formation osseuse chez les malades urémiques et predisent les
anomalies histologiques osseuses.
reflects its content of three residues of the vitamin K-dependent
amino acid, y-carboxyglutamic acid (GLA). BGP in plasma has
the same apparent molecular weight as the pure bone GLA-
protein and studies indicate that the plasma protein is probably
the intact bone protein [31. With the availability of a ra-
dioimmunoassay for detection of BGP in plasma [3], it became
possible to study BGP levels in various pathologic situations
[4—7]. Because bone and kidney may affect blood concentra-
tions of BGP [8, 9], patients without kidney function allowed us
to study the contribution of bone to blood levels of BGP.
Correlations between BGP and other serum biochemical param-
eters as well as histomorphometric parameters of bone in these
patients might help us understand the role of BGP in bone
metabolism and/or its value for predicting underlying bone
histology.
In the present study we measured plasma BGP levels and
other serum biochemical parameters in patients on chronic
maintenance dialysis and evaluated the relationship between
plasma BGP and quantitative static and dynamic parameters of
bone structure, bone formation and resorption. In addition, we
studied the relative values of plasma BGP, serum levels of
alkaline phosphatase, and parathyroid hormone (PTH) for the
prediction of histologic changes in patients with uremic
osteodystrophy.
Methods
Patients. Thirty consecutive patients who were scheduled for
diagnostic bone biopsies were enrolled in the study. There were
18 male patients and 12 female patients with a mean age of 42
3.4 years (range, 13 to 72 years). All patients were on chronic
maintenance dialysis. Twenty-six of them were on hemodialysis
and four on chronic ambulatory peritoneal dialysis. Informed
consent was obtained from all patients before the study. The
duration of dialytic therapy was 32 2.6 months (range, 2 to
108 months). All patients were anuric. None of the patients
were parathyroidectomized or nephrectomized and none of
them had been immobilized. No other medical problems such as
liver cirrhosis, diabetes mellitus, or malabsorption were known
to exist. All patients had normal outdoor activities and were on
Bone Gla-protein (BGP), also referred to as 'osteocalcin,"
represents one of the most abundant non-collagenous bone
proteins [1, 2]. It has a molecular weight of 5800 and the name
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Parameters of bone structure
Bone mass, %
Lamellar osteoid volume, mm3/cm3
Woven osteoid volume, mm3Icm
18.1 1W'
119 21.6
101 1.9
27.8 2.3
20.2 4.3
93.1 14.2
Normal Controls
20.5 3.9"
20.0 10.4
0
Parameters of bone formation and resorption
Lamellar osteoid surface, %
Woven osteoid surface, %
Thickness of lamellar osteoid, p.m
Bone-osteoblast interface, %
Peritrabecular fibrosis, %
Bone-osteoclast interface, %
Parameters of bone dynamics
Mineral apposition rate, p.m/day
Labelled osteoid seams, %
Mineralization lag time, days
53.3 5.0
4.89 0.9
13.5 2.3
3.42 1.0
1.64 0.64
1.69 0.44
0.35 0.06
7.1 2.7
78
11.7 2.1
38.7 3.4
10.6 1.1
21.8 2.5
59.0 13.4
5.94 0.60
1.07 0.08
38 6.6
13 1.6
12.0 4.8
0
9.7 2.8
3.4 2.1
0
1.1 0.35
0.50 0.l5
64.9 16.6
20 6
an unrestricted diet except for potassium and fluids. The
hemodialyzed patients were dialyzed three times weekly, 5 hr
each, using the hollow fiber dialyzer (Cordis Dow Corp.,
Miami, Florida) with 1.5 m2 surface and dialysis machines
(model AK1O, Travenol Laboratories, Inc., Morton Grove,
Illinois). The dialysate contained 3.5 mEq calcium and 2 mEq
magnesium. No concurrent therapy was given with the excep-
tion of routine dialysis support medications including folic acid,
iron, vitamin B6, phosphate binders, and multivitamins.
Bone biopsies. Biopsy specimens were taken from the ante-
rior iliac crest using an electric drill [101. Tetracycline hydro-
chloride was given (Tetracyn®, 500 mg p.o. b.i.d.) on day 19
and 20 before the biopsies, The drug was stopped for the
following 12 days, and subsequently, demeclocycline hydro-
chloride (Declomycin® 300 mg p.o. b.i.d.) was given for 4 days.
Bone biopsy specimens were obtained 4 days thereafter.
Bone histology and histomorphometry. Bone specimens were
fixed in ethanol for 24 hr, dehydrated, and embedded in
methylmethacrylate. Undecalcified sections of 3- and 7- thick-
ness were prepared using a microtome (Model 1140, Jung,
Heidelberg, Germany). The sections were stained with the
modified Goidner's trichrome stain [111, which permits dis-
crimination of calcified bone from osteoid and gives excellent
cellular details [121, Seven-micron thick unstained sections
were prepared for phase-contrast and fluorescence microscopy.
In addition, all slides were stained with a specific histochemical
stain for detection of aluminum in bone [131. The slides were
read without knowledge of clinical or biochemical information.
All sections were analyzed quantitatively for static and dynamic
parameters of bone structure, bone formation, and resorption
using the Osteoplan (Carl Zeiss, Thornwood, New York) ac-
cording to Malluche et al [141. A minimum of 50 optical fields
were evaluated at a magnification of x 200 using an objective
with 0.4 numerical aperture.
Radioimmunoassay for BGP in plasma and dialysate. At
time of bone biopsies, blood samples were taken from all 30
patients for determination of plasma concentrations of BGP.
BGP was measured without knowledge of bone histology in
triplicate using a radioimmunoassay with rabbit antibody di-
rected against calf BGP [31. The antibody crossreacts with
purified human BGP but not with BGP from rat or rabbit bone.
Studies with peptides of known structure derived from enzy-
matic digestion of BGP indicate that the rabbit antibody recog-
nizes the COOH-terminal region of the 49-residue calf bone
protein. All determinations were done with four different dilu-
tions (100, 10, 1, and 0.1 jd) to ascertain agreement between
different dilutions and to assure that results were on scale. The
detection limit of the assay is 0.1 ng, the intraassay variation is
less than 10%, and the intcrassay variation is less than 15% [3].
To determine the effect of dialysis on plasma BGP levels, we
measured plasma BGP in 6 of the 30 patients at the beginning
and the end of a dialysis without ultrafiltration. In addition,
blood samples were obtained before and after passage through
the dialyzer, that is, from arterial and venous sites, and dialy-
sate samples were taken from the outflow of the dialyzer. To
determine day-to-day variations in plasma BGP levels of pa-
tients on chronic maintenance dialysis, we followed prospec-
tively plasma BGP levels in these six patients. For this purpose,
blood was drawn at least once monthly before and after dialysis
for 7 to 9 months. Duration and schedule of dialysis were not
changed during this time.
Biochemical measurements. Serum PTH levels were mea-
sured using a sensitive N-terminal parathyroid hormone ra-
dioimmunoassay which measures intact PTH (anti-human 1—34
PTH, courtesy of Dr. David Endres, Nichols Laboratory, San
Juan Capistrano, California) [15]. Serum concentrations of
calcium were measured by atomic absorption spectropho-
tometry (Perkin-Elmer Model 5000, Norwalk, Connecticut).
Serum phosphate, alkaline phosphatase, and creatinine were
measured with an autoanalyzer (model SMA 12, Technicon,
Tarrytown, New York).
Statistical analysis. Linear regression analysis, multiple re-
gression model analysis, and correlations were calculated be-
tween plasma BGP levels, PTH, alkaline phosphatase, and
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Table I. Static and dynamic quantitative parameters of bone structure, bone formation, and bone resorption in 30 dialyzed uremic patients"
LT-ROD HT-ROD
Abbreviations: LT-ROD, renal osteodystrophy with low bone turnover and osteomalacia; HT-ROD, renal osteodystrophy with high bone
turnover and hyperparathyroid bone disease.
"Values are given as mean SE.
b Normal values obtained from 84 normal American subjects [12]; values are given as mean SD.
Normal values for dynamic parameters were obtained from 28 normal American subjects.
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Ca,mEq/iiter 4.7±0.15 4.6 0.10 4.2—5.1
P, mg/dl 6.14 0.58 7.02 0.61 2.7—4.5
Creatinine, mgldi 8.80 0.7 9.10 0.8 0.5—1.2
AP, IU 71 5.6 214 42 20—70
iPTH, pg/mi 80.2 9.8 195 24.7 11—24
BGP, ng/,nl 47.3 7.9 831 170 6.8 0.2
LT-ROD HT-ROD
Fig. 1. Plasma levels of bone Gla-protein in patients on chronic
maintenance dialysis with low bone turnover and osteomalacia (LT-
ROD) and with high bone turnover and hyperparathyroid bone disease
(HT-ROD).
static and dynamic parameters of bone formation and resorp-
tion. Correlations were calculated with correction for repetitive
sampling.
Differences in serum biochemical parameters between the
two histologic groups of uremic bone disease (see below) were
calculated using the Mann-Whitney Rank Sum test for non-
parametric differences. All computations were done using the
Proc-Gim-In statistical analysis system #979 [16].
Results
Bone histology. Thirteen patients were found to have renal
osteodystrophy with low bone turnover and osteomalacia (LT-
BGP AP PTH
Parameters of bone structure
Bone mass 0.33 0.45 0.17
Lamellar osteoid volume —0.43 —0.33
Woven osteoid volume 073b 0.69a 0.62a
Parameters of bone formation and resorption
Lamellar osteoid surface 0.60 —0.56
Woven osteoid surface 0.84" 0.58a 072b
Bone-osteoblast interface 0•77b 0.66a 072b
Osteoblastic index 078" 0.68a 073b
Peritrabecular fibrosis 091" 076" 084b
Bone-osteoclast interface 0.62a 0.63a 0.56a
Osteoclastic index ofi9 0.63 075b
Parameters of bone dynamics
Mineral apposition rate 0.91" 0.72" 092"
Labelled osteoid seams 0.48 0.54 0.79k'
Mineralization lag time —0.27 —0.24 —0.35
ROD). The other 17 patients had renal osteodystrophy with
high bone turnover and hyperparathyroid bone disease (HT-
ROD). Histomorphometric data in these patients are shown in
Table 1. Renal osteodystrophy with low bone turnover and
osteomalacia was histologically characterized by accumulation
of lamellar osteoid, low or normal number of osteoblasts and
osteoclasts per unit trabecular surface, low fraction of actively
mineralizing (doubly labelled) osteoid seams, decreased mineral
apposition rate and prolonged mineralization lag time (Table 1).
Stainable bone aluminum was seen in 39% of these patients.
The fraction of bone osteoid interface exhibiting stainable bone
aluminum ranged from 62 to 100%. The histologic features of
renal osteodystrophy with high bone turnover and hyper-
parathyroid bone disease were high normal or elevated cancel-
bus bone mass, accumulation of osteoid of abnormal, irregular
"woven" collagen structure, abundance of osteoclasts and
osteoblasts, and peritrabecular fibrosis. The fraction of actively
mineralizing osteoid seams was below normal, yet higher than
in patients with LT-ROD. The mineral apposition rate was high
normal or elevated and mineralization lag time was normal.
Stainable bone aluminum was seen in one of these patients with
12% of the osteoid-bone interface exhibiting stainable bone
aluminum.
Serum biochemistry. There were no significant differences
between serum calcium levels of patients with LT-ROD and
HT-ROD (Table 2). Serum phosphate levels were elevated in
both groups, but there was no difference between LT-ROD and
HT-ROD. Serum alkaline phosphatase levels were at the upper
normal range in patients with LT-ROD and clearly elevated in
patients with HT-ROD. Serum parathyroid hormone levels
were elevated in both groups of patients, and patients with
HT-ROD had significantly higher circulating levels of PTH,
Plasma BGP. Plasma BGP levels were abnormal in all
patients. Patients with HT-ROD had significantly higher plasma
levels of BGP than patients with LT-ROD and there was no
overlap in plasma BGP between the two groups (Fig. 1). The
highest plasma level of BGP in LT-ROD was 121 ng/ml, and the
lowest value of plasma BGP in HT-ROD was 278 ng/ml (normal,
Table 2. Serum biochemical parameters in 30 dialyzed uremic
patients with various types of uremic bone disease'
LT-ROD HT-ROD
Normal
Range
Table 3. Correlations (r-values) between histomorphometric
parameters of bone and bone Gla-protein (BGP), alkaline
phosphatase (AP), and parathyroid hormone (PTH)
a p <0.01.
b p <0.001.
Abbreviations: LT-ROD, Renal osteodystrophy with low bone turn-
over and osteomalacia; HT-ROD, Renal osteodystrophy with high bone
turnover and hyperparathyroid bone disease.
a Values are given as mean SEM.
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6.8 0.2 nglml). Plasma BGP levels measured in six patients at
the beginning of a dialytic therapy were not different before and
after passage through the dialyzer (335 81 vs. 338 48 ng/ml)
and no significant changes were found at the beginning and the
end of a dialysis (335 81 vs. 414 69 ng/ml). BGP
concentrations in dialysate were undetectable in five patients
and 3.4 ng/ml in another patient. Plasma BGP levels drawn
prospectively in six patients before and after dialysis did not
change significantly during 7 to 9 months.
Correlations between plasma BGP and serum biochemistry.
There were no correlations between plasma concentrations of
BGP and serum levels of calcium, phosphate, and creatinine.
However, plasma BGP correlated well with serum alkaline
phosphatase (r = 0.85; P < 0.001) and to a lesser degree with
PTH (r = 0.64; P < 0.01).
Correlations between hone histology, plasma BGP, and
serum biochemistry. Cancellous bone mass correlated neither
with plasma BGP, serum alkaline phosphatase, or PTH. Vol.
ume of lamellar osteoid correlated inversely with BGP but not
with alkaline phosphatase or serum PTH. There was a direct
correlation between volume of woven osteoid, BGP, and PTH.
The surface of lamellar osteoid correlated negatively with BGP
(Fig. 2A) and to a lesser degree with alkaline phosphatase and
PTH. The surface of woven osteoid correlated positively with
BGP (Fig. 2B) and, again, to a lesser degree with alkaline
phosphatase and PTH. Other osteoblastic parameters such as
bone-osteoblast interface, osteoblastic index, and peritra-
becular fibrosis (Fig. 3) were also best correlated with plasma
BGP and less with alkaline phosphatase and PTH. Bone-
osteoclast interface and osteoclastic index correlated equally
with BGP, alkaline phosphatase, and PTH. However, these
correlations were weaker than those between osteoblastic pa-
rameters and BGP. Mineral apposition rate correlated well with
BGP (Fig. 4) and PTH and somewhat less with alkaline
phosphatase, whereas actively mineralizing osteoid seams cor-
related with PTH only. Mineralization lag time did not correlate
with BGP, alkaline phosphatase, or PTH.
Discussion
The observed correlations between BGP and histomor-
phometric parameters of bone indicate that BGP is a good
marker for osteoblastic activity, in particular for bone matrix
and collagen fiber production. This is evidenced by a strong
correlation between BGP and the volume of woven osteoid, the
surface of woven osteoid, and peritrabecular fibrosis. The
negative correlation between BGP and volume and surface of
lamellar osteoid might reflect that, in uremic osteodystrophy,
the appearance of woven osteoid is associated with less lamellar
osteoid [171. The good correlations between BGP and the
number of osteoblasts, bone-osteoblast interface, and mineral
apposition rate further support the notion that BGP is an
indicator of osteoblastic activity. Osteoblastic activity encom-
passes bone formation and mineralization. The lack of correla-
tions between BGP and parameters of bone mineralization,
such as fractional labelling of osteoid and mineralization lag
time, indicates that BGP reflects mainly bone formation activity
by osteoblasts and not bone mineralization in our uremic
patients.
It is of note that BGP levels correlate only marginally with the
extent of active resorption lacunae per trabecular surface and
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